ACTUATE THERAPEUTICS, INC.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Submission of Matters to a Vote of Security Holders

Regulation FD Disclosure

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Other Events

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Regulation FD Disclosure

Submission of Matters to a Vote of Security Holders

Other Events

Entry into a Material Definitive Agreement

Other Events

Regulation FD Disclosure

Regulation FD Disclosure

4.01,9.01

5.02,5.03,8.01,9.01

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration (IPO) statement under Securities Act of 1933

<ITEMS>06b

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

<ITEMS>06b

Registration (IPO) statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement with Pricing Information

Certification of approval for listing and registration on a national securities exchange

Notice of Effectiveness

Registration of Securities on Exchange (amendment)

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

SCHMITT DANIEL M

Zabrowski Dan

Fletcher Aaron G.L.

Huber Martin H. Jr.

Keyes Jason A

RONNEBERG AMY L

Sawhney Roger

THOMSON TODD S

Huber Martin H. Jr.

Voss Capital, LP

Mazar Andrew Paul

LYTLE PAUL J

SCHMITT DANIEL M

SCHMITT DANIEL M

THOMSON TODD S; Kairos Venture Partners II, L.P.

Voss Capital, LP

Kairos Venture Partners II, L.P.

BIOS Fund I, LP

Bios Clinical Opportunity Fund, LP; BP Directors, LP; Bios 2024 Co-Invest, LP; Bios Equity COF, LP

BIOS Fund II NT, LP; BIOS Fund I, LP; BIOS Fund I QP, LP; BIOS Fund II, LP; BIOS Fund II QP, LP; Kreis Leslie W.; Cavu Management, LP; Cavu Advisors, LLC; Bios Equity Partners II, LP; Bios Equity Partners, LP

Annual Report Scanned (Paper)

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Draft registration statement (confidential submission)

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Post-effective amendment filed solely to add exhibits

No description available

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC